INTRODUCTION AND OBJECTIVES:
Pain relief is the key corner of Bladder Pain Syndrome/Interstitial cystitis (BPS/IC) management. The present prospective, randomized, double-blind, placebocontrolled (saline) clinical trial aims to evaluate the analgesic efficacy and safety of intra-trigonal injection of OnaBotA in patients with BPS/IC refractory to common treatment.
METHODS: Nineteen women with a pain score more than 4 in a 0-10 visual analogue scale (VAS) were enrolled. Patients were randomized to receive 100 Units (U) in 10 ml of saline (n¼10) of OnaBotA (Botox) or the equivalent volume of saline (n¼9) in 10 points of the bladder trigone under cystoscopic guidance and general anaesthesia. The primary outcome was VAS at 12 weeks (w). Secondary outcomes included VAS at 4 and 8w, day and night time frequency in a 3-day bladder diary, O'Leary-Sant score (OSS) and QoL 4, 8 and 12w after treatment. Treatment Benefit Scale (TBS) was evaluated at 12w. Side effects were registered, in particular post-void residual volumes (PVR) and urinary tract infections (UTIs). Results are presented as mean values AE standard deviation. T-test was used to compare the 2 arms at each time point.
RESULTS: Mean age was identical (OnaBotA: 44AE10y vs Saline: 48AE11y). According to ESSIC classification each arm had 3 cases with Hunner lesions. At baseline the two groups were balanced for all clinical variables (table 1). At 12w VAS for pain was significantly lower in OnaBotA arm (3.1AE2.8 versus 5AE2.2, p<0.05). VAS was numerically lower in OnaBotA arm also at 4 and 8w (table 1) . OSS, and QoL were significantly better in the OnabotA arm at 8 and 12w (table 1) . Urinary frequency was numerically lower in OnaBotA arm (table 1). Treatment Benefit Scale was 1.9AE0.9 in the OnabotA group versus 3.1AE0.8 in the Saline group (p<0.05). Five UTIs occurred, 2 in Saline and 3 in the OnaBotA arms. No cases of voiding dysfunction were observed.
CONCLUSIONS: This RCT demonstrates that intra-trigonal injection of 100U of OnaBotA is significantly better than placebo to reduce pain and to improve QoL in patients with refractory BPS/IC. Adverse events associated with intra-trigonal injection of 100U of OnaBotA were mild. No cases of urinary retention occurred.
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Shun Takai*, Pittsburgh, PA; Tsuyoshi Majima, Nagoya, Japan; Takahiro Shimizu, Kochi, Japan; Naoki Wada, Asahikawa, Japan; Nobutaka Shimizu, Takahisa Suzuki, Eiichiro Takaoka, Pittsburgh, PA; Momokazu Gotoh, Nagoya, Japan; William Goins, Joseph Glorioso, Naoki Yoshimura, Pittsburgh, PA INTRODUCTION AND OBJECTIVES: Increased afferent excitability is considered to be an important pathophysiological basis of interstitial cystitis/bladder pain syndrome (IC/BPS) and overactive bladder (OAB). Also, transient receptor potential vanilloid 1 (TRPV1) receptors are known to be involved in afferent sensitization. Therefore, we investigated the effect of gene therapy with HSV vectors encoding PL or PP1a, a negative regulator of TRPV1, using a rat model of longlasting cystitis induced by hydrogen peroxide (HP).
METHODS: HSV vectors encoding green fluorescent protein (GFP), PL or PP1a were injected into the bladder wall of female SD rats. One week later, 1% HP or normal saline (NS) was administered into the bladder. Awake cystometry (CMG), resiniferatoxin (RTX)-induced nociceptive behaviors such as licking and freezing, NGF mRNA expression in the bladder, bladder weight and histology were evaluated 2 weeks after viral injection.
RESULTS: In CMG, the GFP/HP group showed a significant decrease in intercontraction intervals compared to the GFP/NS group, which were significantly prolonged by 57.8% and 68.0% in PL/HP and PP1a/HP groups (p<0.01), respectively. The number of freezing behavior was significantly lower in PL/HP and PP1a/HP groups by 86.1% and 93.5%, respectively, compared to the GFP/HP group. Compared with the GFP/NS group, the GFP/HP group had significantly heavier bladder weight, whereas the PL/HP group and PP1a/HP group showed significantly lighter bladder weight than the GFP/HP group. Hematoxylin and eosin staining of bladder sections showed substantial inflammation characterized by inflammatory cell infiltration, and detrusor hypertrophy in the bladder in the GFP/HP group compared with GFP/ NS group, which were alleviated in PL/HP and PP1a/HP groups. In RT-PCR, the GFP/HP group showed higher significantly (p<0.05) expression of NGF mRNA in the bladder mucosa than the GFP/NS group, which was significantly decreased in the PL/HP and PP1a/HP groups (p < 0.05).
CONCLUSIONS: HSV vectors-mediated gene delivery of PL or PP1a significantly reduced bladder overactivity and enhanced bladder pain sensitivity in HP cystitis rats. Also, both treatments can reduce bladder inflammatory changes and increased bladder weight at least in part through amelioration of NGF overexpression in the bladder mucosa. Thus, HSV-mediated TRPV1-targeting gene therapy could be effective for the treatment of IC/BPS including Hunner-type IC that is often associated with bladder inflammation. . 197, No. 4S, Supplement, Friday, May 12, 2017 
